| abstract |
Compounds which form covalent bonds with brutonyl tyrosine kinase (Btk) are disclosed herein. Non-irreversible inhibitors of Btk are also described. In addition, reversible inhibitors of Btk are also described. Also disclosed are pharmaceutical compositions comprising such compounds. Methods of using Btk inhibitors alone or in combination with other therapeutic agents for the treatment of autoimmune diseases or conditions, differentimmune diseases or conditions, cancers including lymphomas, and inflammatory diseases or conditions are disclosed. |